

Check for updates

Research Article

Association of vitamin E on the risk of ovarian cancer: a meta-analysis

Youxu Leng^{1,*}, Hairong Zhou^{2,*}, Fanjing Meng³, Tian Tian⁴, Jianying Xu⁴ and Fengjuan Yan²

¹Department of Gynecology, Longhua District Central Hospital, Shenzhen, 518110, Guangdong Province, China; ²Department of General Medical Department, Longhua District Central Hospital, Shenzhen, 518110, Guangdong Province, China; ³Department of Gynecology, Longhua District People's Hospital, Shenzhen 518109, Guangdong Province, China; ⁴Department of Gynecology, Dongguan City Tangxia Hospital, Dongguan 523710, Guangdong Province, China

Correspondence: Youxu Leng (leng_youxu@163.com)



Many researches were conducted to assess the association of vitamin E intake on the risk of ovarian cancer, with conflict results. The current meta-analysis of published observational studies aimed to investigate the effect of vitamin E intake on ovarian cancer risk. The summary relative risks (RRs) with corresponding 95% confidence intervals (CIs) were calculated to measure the effectiveness of vitamin E intake on ovarian cancer risk using a random-effects model. As a result, 14 studies including 4597 patients were identified. Eleven studies reported about total vitamin E intake, eight studies about vitamin E intake from food only and five studies about vitamin E intake from supplement only on the risk of ovarian cancer. Overall, the summary RRs on ovarian cancer risk was 0.95 (95%CIs = 0.78–1.16) in total vitamin E intake, 0.99 (95%CIs = 0.77–1.27) in vitamin E intake from food only and 0.82 (95%CIs = 0.54–1.25) in vitamin E intake from supplement only. Results in subgroup analyses by study design and geographic location were consistent with overall result. In conclusions, the findings of this meta-analysis suggested that high intake of vitamin E from food or vitamin E supplement had no significant effect on the risk of ovarian cancer.

Introduction

Ovarian cancer is one of the most common malignant tumors in women, accounting for 2.5% of female cancers [1]. About 13,850 women die each year from ovarian cancer; this may be the main causes of cancer death in United States among females [2,3]. Furthermore, the 5-year survival rate with all types of ovarian cancer is about 47% [2,3]. Health education and diet prevention are important ways of preventing ovarian cancer. Vitamin E, also named as tocopherol, contains putative anti-cancer and anti-mutant substances that have long been considered to prevent cancer. It is also a well-known powerful antioxidant, which could protect cells against from oxidative DNA damage and mutagenesis, thereby preventing the onset of certain tumors [4,5]. Previous meta-analyses had been published to explore vitamin E intake on many tumors, such as lung cancer [6], esophageal cancer [7], uterine cervical neoplasm [8] and so on. To our attention, a lot of studies have investigated vitamin E intake from food or from supplement on the risk of ovarian cancer, resulting in inconsistent findings. The reasons for these differences included small sample size, low statistical capacity and/or clinical heterogeneity. To overcome the limitations of individual research and address these inconsistencies, we conducted this meta-analysis to provide a comprehensive overview.

*These authors contributed equally to this work.

Received: 16 September 2019 Revised: 02 November 2019 Accepted: 15 November 2019

Accepted Manuscript online: 27 November 2019 Version of Record published: 23 December 2019

Materials and methods Search strategy

To collect studies that met the criteria for this meta-analysis, we reviewed all literature on the relationship between vitamin E and ovarian cancer risk. Literature searches were performed using Web of Science, EMBASE and PubMed databases (up to June 1, 2019). The following key words and subject terms were used



in the search: "vitamin E" OR "vitamin*" OR "tocopherol" combined with "ovarian cancer" OR "ovarian tumor". We also manually screened the bibliography of original research and review articles. The initial qualification is determined independently by the two reviewers. Disagreements between the reviewers are resolved by a third-party reviewer at a consensus meeting.

Inclusion criteria and exclusion criteria

To be included in the meta-analysis, these studies must be: (1) case–control, cross-sectional or cohort studies; (2) patients were diagnosed as ovarian cancer; (3) report relative risks (RRs) and 95% confidence intervals (CIs) about vitamin E and ovarian cancer. When two or more articles report the same data, the most recently updated data will be considered. The two reviewers screened the titles and abstracts of the records retrieved from the literature. The full text of the potential related articles is independently searched and evaluated by two reviewers, and the differences in research qualifications are resolved by a third author.

The exclusion criteria were as follows: (1) case reports, conference abstracts, letters, editorials, reviews; (2) overlapping or duplicate studies; (3) irrelevant studies; (4) no available data of RRs and 95%CIs and (5) animal studies.

Data extraction

Two investigators independently extracted these information from all eligible studies selected according to predefined criteria. Data were extracted about the last name of first author, age, study design, country, cases and participants, RR and 95%CI, sources of vitamin E (total vitamin E, vitamin E from food or vitamin E from supplement) and category of vitamin E on ovarian cancer risk.

Statistical analysis

All statistical analyses were conducted using the STATA software V.12.0 (STATA Corp, College Station, Texas, U.S.A.). We conducted a meta-analysis of the relationship about vitamin E on ovarian cancer risk. Pooled results were expressed as RRs and 95%CIs with a random-effect model [9]. We used Cochran Q statistic and I^2 to assess variation and heterogeneity within and between studies [10]. The heterogeneity test was used to evaluate the null hypothesis that all studies evaluated the same effect. When the Q test P < 0.05 or $I^2 > 50\%$, it is suggested that the study may be heterogeneous [11]. Sensitivity analysis was used to explore whether one single study had the essential effect on the overall RRs. To assess publication bias, visual observations using the Egger test [12] and the funnel plot [13] were used. When P < 0.05, the difference was statistically significant.

Results

Studies included in the meta-analysis

We identified 731 studies using electronic and manual retrieval methods, 394 of which were excluded because they were copies of other reports. Of the remaining 337 articles, 292 articles were excluded after review based on the title and abstract, and 45 were reviewed in full-text. Meanwhile, 31 articles were excluded due to reasons present in Figure 1. Finally, a total of 14 articles [14–27] involving 4597 cases met the inclusion criteria of this meta-analysis. Five articles were cohort design and the remaining nine articles were case—control design. All the studies come from North America except one from Asia. Table 1 summarizes some of the basic features of all included studies.

Total vitamin E intake and ovarian cancer risk

Eleven studies [14–18,22–27] with 3520 cases reported total vitamin E intake on the risk ovarian cancer. Meta-analysis revealed that high category of total vitamin E intake had no significant effect on the risk of ovarian cancer (RRs = 0.95, 95%CIs = 0.78–1.16, I^2 = 53.2%, $P_{\text{for heterogeneity}}$ = 0.019) (Figure 2). Four studies were cohort design and seven studies were with case–control design. Subgroup analysis by study design showed that the summary RRs on ovarian cancer risk was 1.14 (95%CIs = 0.94–1.38, I^2 = 0.0%, $P_{\text{for heterogeneity}}$ = 0.417) in cohort studies and 0.84 (95%CIs = 0.64–1.11, I^2 = 55.6%, $P_{\text{for heterogeneity}}$ = 0.036) in case–control studies. Meanwhile, we further explore the association between ovarian cancer and geographic location. The results suggested that total vitamin E intake is not associated with the risk of ovarian cancer in North America (RRs = 1.02, 95%CIs = 0.88–1.19, I^2 = 16.8%, $P_{\text{for heterogeneity}}$ = 0.288).

Vitamin E intake from food only and ovarian cancer risk

Eight studies [16–20,23–25] with 2430 cases about vitamin E intake from food only on ovarian cancer risk were included. Overall, the summary RRs on ovarian cancer risk was 0.99 (95%CIs = 0.77-1.27, $I^2 = 52.8\%$, $P_{\text{for heterogeneity}}$






Figure 1. Flow chart of meta-analysis for exclusion/inclusion of studies

= 0.038) in vitamin E intake from food only (Figure 2). Four studies were cohort design and the remaining four studies were with case–control design. Subgroup analysis by study design showed high category of vitamin E intake from food only had no significant association on ovarian cancer risk either in cohort studies (RRs = 1.08, 95%CIs = 0.83–1.40, I^2 = 35.9%, $P_{\text{for heterogeneity}}$ = 0.197) or in case–control studies (RRs = 0.91, 95%CIs = 0.57–1.46, I^2 = 60.8%, $P_{\text{for heterogeneity}}$ = 0.054).

Vitamin E intake from supplement only and ovarian cancer risk

Five studies [17,18,21,24,25] with 1672 cases reported vitamin E intake from supplement only on the risk of ovarian cancer. Overall, the summary RRs of vitamin E intake from supplement only on ovarian cancer risk was 0.82 (95%CIs = 0.54-1.25, $I^2 = 82.3\%$, $P_{\text{for heterogeneity}} < 0.001$).

Publication bias and sensitivity analysis

To assess publication bias, Begg's test was conducted. After the analysis is complete, we did not detect any significant publication bias in total vitamin E intake (P = 0.620), in vitamin E intake from food only (P = 0.876) and in vitamin



Table 1 Characteristics of each individual study included in our analysis

Study, Year	Design	Age	Participants, Cases				
				Country	Source of vitamin E	Category	RR (95%CI)
Chang et al., 2007	Cohort	<84	97,275, 280	United States	Total vitamin E intake	>207 versus ≤7 mg/d	1.46(0.76–2.79)
Cramer et al., 2001	PBCC	>50	1065, 549	United States	Total vitamin E intake	Q5 versus Q1	0.97(0.64–1.49)
Fairfield et al., 2001	Cohort	30–55	80,326, 301	United States	Total vitamin E intake From food	327 IU/day versus 5 IU/day 12 IU/day versus 5 IU/day	0.88(0.61–1.27) 1.52(1.04–2.21)
Fleischauer et al., 2001	HBCC	≥18	419, 168	United States	Total vitamin E intake From food From supplement	>43.5 versus <11.0 mg/d >10.5 versus <6.5 mg/d >30 mg/d versus none	0.59(0.30-1.15) 1.82(0.90-3.69) 0.43(0.26-0.72)
Gifkins et al., 2012	PBCC	>21	595, 205	United States	Total vitamin E intake From food From supplement	>114.9 versus <21.7 mg/d >11.6 versus <7.4 mg/d Yes versus no	1.03(0.59–1.78) 0.89(0.45–1.77) 1.63(1.02–2.63)
Kushi et al., 1999	Cohort	55–69	29,083, 139	United States	From food	>24.4 versus <6.2 mg/d	0.91(0.56–1.48)
McCann et al., 2001	HBCC	20–87	1921, 496	United States	From food	>9.4 versus ≤4.9 mg/d	0.58(0.38–0.88)
Pan et al. 2004	PBCC	20–76	2577, 442	Canada	From supplement	≥10 years versus never	0.49(0.30-0.81)
Salazar-Martinez et al., 2002	HBCC	20–79	713, 84	Mexico	Total vitamin E intake	≥9.4 versus ≤6.3 mg/d	1.60(0.88–2.95)
Silvera et al., 2006	Cohort	40–59	89,835, 264	Canada	Total vitamin E intake From food	>28 versus <17 mg/d >25 versus <17 mg/d	1.24(0.85–1.82) 0.87(0.57–1.31)
Terry et al. 2017	PBCC	20–79	1038, 406	United States	Total vitamin E intake From food From supplement	>25.8 versus <6.7 mg/d >9.1 versus <4.1 mg/d ≥13.5 mg/d versus never	0.91(0.61-1.37) 0.90(0.49-1.67) 0.86(0.61-1.20)
Thomson et al., 2008	Cohort	50–79	133,614, 451	United States	Total vitamin E intake From food From supplement	$>$ 403.2 versus $<$ 7.4 mg/d $>$ 9.4 versus \le 4.9 mg/d $>$ 200 mg/d versus never	1.22(0.89-1.66) 1.05(0.71-1.57) 1.12(0.86-1.45)
Tung et al., 2005	PBCC	45–75	1165, 558	United States	Total vitamin E intake	Q4 versus Q1	0.80(0.56–1.16)
Zhang et al., 2004	HBCC	18–75	906, 254	China	Total vitamin E intake	\geq 38.55 versus \leq 23.40 mg/d	0.41(0.24-0.70)

Abbreviations: CI, confidence intervals; HBCC, hospital-based case-control study; PBCC, population-based case-control study; RR, relative risk.

E intake from supplement only (P = 0.365). Figure 3 shows the funnel plot about total vitamin E intake and ovarian cancer risk. Sensitivity analyses indicated that no singly study had essential effect on the overall results.

Discussion

Numerous of studies about vitamin E intake and ovarian cancer risk have been published, with conflicting results. We therefore conducted the present study to clarify whether high category of total vitamin E intake, vitamin E intake from food and vitamin E intake from supplement had some effective on the development of ovarian cancer. A total of 14 papers involving 4597 ovarian cancer cases were used in the present study. Pooled results suggested that high category of total vitamin E intake, vitamin E intake from food only and vitamin E intake from supplement only are not associated with the risk of ovarian cancer. Subgroup analyses by geographic location and study design in total vitamin E intake and subgroup analysis by study design in vitamin E intake from food only obtained consistent results with overall result. These results of the present study suggested to clinicians and researchers that there is no need to supplement vitamin E or intentionally eat more vitamin E.

Between-study heterogeneity existed in our study, which may affect the conclusions of the meta-analysis, although random effects model have been carried out. We used meta-regression to explore the potential heterogeneity. To our attention, geographic location may be a covariate for this high heterogeneity in total vitamin E intake. When we performed the subgroup analysis by geographic location, the I^2 was reduced to 16.8% in North America populations and no analysis for Asia due to only one study from Asia. The result was not changed in North America. We did not






Figure 2. The forest plot about total vitamin E intake, vitamin E intake from food and vitamin E intake from supplement on ovarian cancer risk

detect any other influence factors on this high heterogeneity in total vitamin E intake, vitamin E intake from food and vitamin E intake from supplement.

Previous review by Koushik et al. [28] had explored the association about vitamin E intake on ovarian cancer risk from Pooling Project investigations of ovarian cancer risk. They concluded that consumption of vitamin E did not play a major role in ovarian cancer risk. Another review published by Crane et al. [29] concluded that no association was demonstrated for vitamin E intake on ovarian cancer risk while only included three papers. Results in the current meta-analysis were consistent with the previous reviews. Although our study did not obtain a positive result, we included more studies than the above-mentioned reviews. Furthermore, we also explored the association about total vitamin E intake, vitamin E intake from food and vitamin E intake from supplement on ovarian cancer risk, respectively. Even though, trial sequential analysis should be performed to see if more investigations were needed [30].

Some limitations should be stated in this meta-analysis. First, any literature-based review and meta-analysis are facing a major threat, namely reporting bias (only recruiting published English literature). Second, the sample size of some studies is relatively small. Third, almost all the included studies come from North America, and the results in our study are suitable for North America only. Therefore, to explore the relationship about vitamin E on the risk of ovarian cancer, more studies with other countries are warranted to further confirm this result. There is no doubt that






Figure 3. Funnel plot for the analysis of publication bias between total vitamin E intake and ovarian cancer risk

the limitations mentioned above may affect our final conclusions. However, this meta-analysis also has its advantages. To the best of our knowledge, our meta-analysis is the comprehensive evidence to provide vitamin E intake on ovarian cancer risk. Similarly, compared with individual studies, our data on the relationship between vitamin E intake and ovarian cancer risk, due to the results of multiple independent analysis, improved statistical power and resolution, resulting in higher accuracy. However, given the limitations described above, further research is needed to address bias, confusion and opportunity.

Conclusions

In conclusions, the findings of this meta-analysis indicated that high intake of vitamin E from food or vitamin E supplement had no significant effect on the risk of ovarian cancer. More studies are required to further explore these associations due to some limitations existed in our study.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

The authors declare that there are no sources of funding to be acknowledged.

Author Contribution

Y.X.L. and H.R.Z. contributed to the conception and design of this research. Y.X.L., H.R.Z. and F.J.M. contributed to the completion of articles, the data extraction. T.T. calculated the data. Y.X.L. and J.Y.X. write the manuscript. F.J.Y. reviewed and revised the manuscript. The entire author approved the final manuscript.



Abbreviations

CI, confidence interval; HBCC, hospital-based case-control study; PBCC, population-based case-control study; RR, relative

References

- 1 Jelovac, D. and Armstrong, D.K. (2011) Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 61, 183–203, https://doi.org/10.3322/caac.20113
- 2 Jemal, A., Siegel, R., Xu, J. and Ward, E. (2010) Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300, https://doi.org/10.3322/caac.20073
- 3 Nasioudis, D., Ko, E.M., Haggerty, A.F., Giuntoli, II, R.L., Burger, R.A., Morgan, M.A. et al. (2019) Isolated distant lymph node metastases in ovarian cancer. Should a new substage be created? *Gynecol. Oncol. Rep.* 28, 86–90, https://doi.org/10.1016/j.gore.2019.03.008
- 4 Diao, Q.X., Zhang, J.Z., Zhao, T., Xue, F., Gao, F., Ma, S.M. et al. (2016) Vitamin E promotes breast cancer cell proliferation by reducing ROS production and p53 expression. *Eur. Rev. Med. Pharmacol. Sci.* 20, 2710–2717
- 5 Zheng, N., Gao, Y., Ji, H., Wu, L., Qi, X., Liu, X. et al. (2016) Vitamin E derivative-based multifunctional nanoemulsions for overcoming multidrug resistance in cancer. J. Drug Target. 24, 663–669, https://doi.org/10.3109/1061186X.2015.1135335
- 6 Zhu, Y.J., Bo, Y.C., Liu, X.X. and Qiu, C.G. (2017) Association of dietary vitamin E intake with risk of lung cancer: a dose-response meta-analysis. *Asia Pac. J. Clin. Nutr.* **26**, 271–277
- 7 Cui, L., Li, L., Tian, Y., Xu, F. and Qiao, T. (2018) Association between Dietary Vitamin E Intake and Esophageal Cancer Risk: An Updated Meta-Analysis. Nutrients 10, pii: E801, https://doi.org/10.3390/nu10070801
- 8 Hu, X., Li, S., Zhou, L., Zhao, M. and Zhu, X. (2017) Effect of vitamin E supplementation on uterine cervical neoplasm: A meta-analysis of case-control studies. *PLoS One* **12**, e0183395, https://doi.org/10.1371/journal.pone.0183395
- 9 DerSimonian, R. and Laird, N. (1986) Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188, https://doi.org/10.1016/0197-2456(86)90046-2
- 10 Higgins, J.P., Thompson, S.G., Deeks, J.J. and Altman, D.G. (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557–560, https://doi.org/10.1136/bmj.327.7414.557
- 11 Higgins, J.P. and Thompson, S.G. (2004) Controlling the risk of spurious findings from meta-regression. Stat. Med. 23, 1663–1682, https://doi.org/10.1002/sim.1752
- 12 Egger, M., Davey Smith, G., Schneider, M. and Minder, C. (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* **315**, 629–634, https://doi.org/10.1136/bmi.315.7109.629
- 13 Begg, C.B. and Mazumdar, M. (1994) Operating characteristics of a rank correlation test for publication bias. *Biometrics* **50**, 1088–1101, https://doi.org/10.2307/2533446
- 14 Chang, E.T., Lee, V.S., Canchola, A.J., Clarke, C.A., Purdie, D.M., Reynolds, P. et al. (2007) Diet and risk of ovarian cancer in the California Teachers Study cohort. *Am. J. Epidemiol.* **165**, 802–813, https://doi.org/10.1093/aje/kwk065
- 15 Cramer, D.W., Kuper, H., Harlow, B.L. and Titus-Ernstoff, L. (2001) Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women. *Int. J. Cancer* **94**, 128–134, https://doi.org/10.1002/ijc.1435
- 16 Fairfield, K.M., Hankinson, S.E., Rosner, B.A., Hunter, D.J., Colditz, G.A. and Willett, W.C. (2001) Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. *Cancer* **92**, 2318–2326, https://doi.org/10.1002/1097-0142(20011101)92:9%3c2318::AID-CNCR1578%3e3.0.C0;2-7
- 17 Fleischauer, A.T., Olson, S.H., Mignone, L., Simonsen, N., Caputo, T.A. and Harlap, S. (2001) Dietary antioxidants, supplements, and risk of epithelial ovarian cancer. *Nutr. Cancer* 40, 92–98, https://doi.org/10.1207/S15327914NC402'3
- 18 Gifkins, D., Olson, S.H., Paddock, L., King, M., Demissie, K., Lu, S.E. et al. (2012) Total and individual antioxidant intake and risk of epithelial ovarian cancer. *BMC Cancer* 12, 211–220, https://doi.org/10.1186/1471-2407-12-211
- 19 Kushi, L.H., Mink, P.J., Folsom, A.R., Anderson, K.E., Zheng, W., Lazovich, D. et al. (1999) Prospective study of diet and ovarian cancer. *Am. J. Epidemiol.* **149**, 21–31, https://doi.org/10.1093/oxfordjournals.aje.a009723
- 20 McCann, S.E., Moysich, K.B. and Mettlin, C. (2001) Intakes of selected nutrients and food groups and risk of ovarian cancer. Nutr. Cancer 39, 19–28, https://doi.org/10.1207/S15327914nc391'3
- 21 Pan, S.Y., Ugnat, A.M., Mao, Y., Wen, S.W., Johnson, K.C. and Canadian Cancer Registries Epidemiology Research, G (2004) A case-control study of diet and the risk of ovarian cancer. *Cancer Epidemiol. Biomarkers Prev.* **13**, 1521–1527
- 22 Salazar-Martinez, E., Lazcano-Ponce, E.C., Gonzalez Lira-Lira, G., Escudero-De los Rios, P. and Hernandez-Avila, M. (2002) Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. *Oncology* **63**, 151–157, https://doi.org/10.1159/000063814
- 23 Silvera, S.A., Jain, M., Howe, G.R., Miller, A.B. and Rohan, T.E. (2006) Carotenoid, vitamin A, vitamin C, and vitamin E intake and risk of ovarian cancer: a prospective cohort study. *Cancer Epidemiol. Biomarkers Prev.* **15**, 395–397, https://doi.org/10.1158/1055-9965.EPI-05-0835
- 24 Terry, P.D., Qin, B., Camacho, F., Moorman, P.G., Alberg, A.J., Barnholtz-Sloan, J.S. et al. (2017) Supplemental Selenium May Decrease Ovarian Cancer Risk in African-American Women. *J. Nutr.* **147**, 621–627, https://doi.org/10.3945/jn.116.243279
- 25 Thomson, C.A., Neuhouser, M.L., Shikany, J.M., Caan, B.J., Monk, B.J., Mossavar-Rahmani, Y. et al. (2008) The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. *Nutr. Cancer* **60**, 710–719, https://doi.org/10.1080/01635580802233983
- 26 Tung, K.H., Wilkens, L.R., Wu, A.H., McDuffie, K., Hankin, J.H., Nomura, A.M. et al. (2005) Association of dietary vitamin A, carotenoids, and other antioxidants with the risk of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14, 669–676, https://doi.org/10.1158/1055-9965.EPI-04-0550
- 27 Zhang, M., Lee, A.H. and Binns, C.W. (2004) Reproductive and dietary risk factors for epithelial ovarian cancer in China. *Gynecol. Oncol.* 92, 320–326, https://doi.org/10.1016/j.ygyno.2003.10.025



- 28 Koushik, A., Wang, M., Anderson, K.E., van den Brandt, P., Clendenen, T.V., Eliassen, A.H. et al. (2015) Intake of vitamins A, C, and E and folate and the risk of ovarian cancer in a pooled analysis of 10 cohort studies. *Cancer Causes Control.* **26**, 1315–1327, https://doi.org/10.1007/s10552-015-0626-0
- 29 Crane, T.E., Khulpateea, B.R., Alberts, D.S., Basen-Engquist, K. and Thomson, C.A. (2014) Dietary intake and ovarian cancer risk: a systematic review. *Cancer Epidemiol. Biomarkers Prev.* **23**, 255–273, https://doi.org/10.1158/1055-9965.EPI-13-0515
- 30 Fu, W., Zhuo, Z.J., Chen, Y.C., Zhu, J., Zhao, Z., Jia, W. et al. (2017) NFKB1 -94insertion/deletion ATTG polymorphism and cancer risk: Evidence from 50 case-control studies. *Oncotarget* **8**, 9806–9822